Home › Is compounded semaglutide safe?
Last reviewed 2026-09-01 · FDA text read 2026-09-01
Is compounded semaglutide safe? Here is what the FDA has published
This page does not answer the question in its title, because no public record can. It gives you what the FDA has published: that compounded drugs are not FDA-approved and not reviewed before marketing, the adverse-event reports it has received with its own caveats, and how to read the inspection record of the pharmacy that made yours.
What the FDA says about compounded drugs
A compounded drug might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available. However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.
That is the FDA's framing for every compounded drug, not a statement about any particular pharmacy's product. The FDA's page is dated (content current as of September 1, 2026 when read) and is the source for everything in the next section too. The status of compounded semaglutide itself, shortage, bulks list and the pending proposal, is on its own dated page.
Adverse-event reports, with the FDA's caveats
The FDA publishes a running count of adverse-event reports it has received for compounded GLP-1 drugs. The count is never shown here without the two sentences the FDA puts around it.
FDA has received reports of adverse events related to compounded versions of semaglutide and tirzepatide. However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported. Many of the adverse events reported for compounded products appear to be consistent with adverse events related to the FDA-approved versions of these products.
As of May 31, 2026, the FDA has received:
990 reports of adverse events associated with compounded semaglutide.
more than 730 reports of adverse events associated with compounded tirzepatide.
It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events.
Two things follow from the FDA's own wording. The number is a count of reports, not of confirmed harms. And it is a count from a system that, in the FDA's words, state-licensed pharmacies are not required to report into, so it is not a rate.
What the FDA tells patients to check
Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy.
The agency urges consumers to be vigilant when purchasing drugs online and only purchase from state-licensed pharmacies.
“State-licensed” is a checkable fact, and so is “FDA-registered”. They are different things: a 503A pharmacy holds a state license and answers to its state board; a 503B outsourcing facility registers with the FDA and is inspected by the FDA. 503A vs 503B, in the statute's words sets out both. Either way, the name on your label is the name to check.
What an FDA inspection record is, and is not
For a 503B facility, the FDA publishes the date of its last inspection, whether a Form 483 was issued, whether a recall was conducted, and what action followed. This site republishes those columns for every registered facility. Two of them are routinely over-read, so here is the FDA's own description of a Form 483:
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations. The FDA Form 483 is considered, along with a written report called an Establishment Inspection Report, all evidence or documentation collected on-site, and any responses made by the company. The Agency considers all of this information and then determines what further action, if any, is appropriate to protect public health.
“Open” in the action column means the FDA has not finalised the inspection's classification. It is not a finding. A warning letter is a finding of a kind, and the FDA posts the letter; where it has, the record here links it.
Look up the pharmacy on your label
Type the name printed on the compounded product. A match shows the FDA's inspection columns for that facility with the FDA's date. No match usually means a state-licensed 503A pharmacy; the state board of pharmacy for the state on the label holds its license, and the NABP directory lists every board.
Where to report a problem
If you have had an adverse event with a compounded drug, the FDA's channel is MedWatch; a report there is how the count above grows. A complaint about the pharmacy itself goes to its state board.
Common questions
Does the FDA say compounded semaglutide is unsafe?
No such sentence exists on the FDA's page, and this site will not write one. What the FDA says is that compounded drugs "are not FDA approved", that "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed", and that it has received adverse-event reports which are "likely underreported". Those are the sentences; the judgement is yours and your prescriber's.
Are the adverse-event reports proof that a product caused harm?
The FDA says not on their own: "it is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events." It also notes that many reported events "appear to be consistent with adverse events related to the FDA-approved versions of these products." A count is a count of reports, with the date the FDA attached to it.
Does a Form 483 on the pharmacy's record mean it is unsafe?
A Form 483 is the list of observations an FDA investigator leaves at the end of an inspection. The FDA's own FAQ says it "does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations." Most inspected 503B facilities on the FDA's list have received one. What the FDA did next is on the same record: nothing yet, a regulatory meeting, or a warning letter.
Is a 503B outsourcing facility safer than a 503A pharmacy?
This site does not say. The two are inspected by different regulators and held to different standards, and each leaves a public record you can read. Our page on 503A vs 503B sets out the statute; the lookup on this page tells you which kind made yours.
Sources, read 2026-09-01: FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 09/01/2026); FDA, FDA Form 483 Frequently Asked Questions (content current as of 01/09/2020). Every quotation is verbatim; nothing on this page is medical advice. See methodology.